Zydus Lifesciences Limited — Others, 16-07-2025: Shareholders meeting

The company has announced its Integrated Annual Report for the financial year ended March 31, 2025. The company delivered a strong financial performance, with total income at 23,511 Cr, EBITDA at 7,058.5 Cr, and net profit reaching 4,672.6 Cr. The company maintains a robust net cash position of 4,883.6 Cr and has proposed a dividend of 11 rupees per share. Operationally, the company saw broad-based growth in its India, US, and International markets. Key highlights include advancements in R&D, positive US FDA inspection outcomes, and strategic acquisitions in consumer wellness and medtech.